Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 236Carcinoma, Non-Small-Cell Lung 78Carcinoma, Renal Cell 61Neoplasm Metastasis 52Neoplasms 47Prostatic Neoplasms 34Uveal Melanoma 29Lung Neoplasms 28Pancreatic Neoplasms 27Carcinoma, Hepatocellular 25Brain Neoplasms 23Sarcoma 22Colorectal Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Skin Neoplasms 17Kidney Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Mesothelioma 13Uterine Cervical Neoplasms 12Recurrence 12Glioblastoma 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 6TH 302 4Radiotherapy 4pimonidazole 3fluoroazomycin arabinoside 3Propofol 3Injections 3Positron Emission Tomography Computed Tomography 2Blood Specimen Collection 2Bacterial Load 2pomalidomide 1pembrolizumab 1inositol trispyrophosphate 1gadobutrol 1fluoromisonidazole 1fludarabine 1Tirapazamine 1Temozolomide 1Sodium Chloride 1Sevoflurane 1Saline Solution 1Pancreaticoduodenectomy 1Paclitaxel 1Oxygen 1Nitroglycerin 1Nimorazole 1NVP-BKM120 1Metformin 1Magnetic Resonance Spectroscopy 1Ketamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypoxia × Ipilimumab × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡